Skip to main content

Advertisement

SpringerLink
Log in

The impact of SGLT 2 inhibitors: Heart failure and beyond

  • Letter to the Editor
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dunbar SB, Khavjou OA, Bakas T et al (2018) Projected costs of informal caregiving for cardiovascular disease: 2015 to 2035: A policy statement from the American Heart Association. Circulation 137. https://doi.org/10.1161/cir.0000000000000570

  2. Hinton W, McGovern A, Coyle R et al (2018) Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open 8:e020282. https://doi.org/10.1136/bmjopen-2017-020282

    Article  PubMed  PubMed Central  Google Scholar 

  3. Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 ACC/AHA/HFSA guideline for the management of heart failure. J Card Fail 28:e1–e167. https://doi.org/10.1016/j.cardfail.2022.02.010

    Article  Google Scholar 

  4. McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/nejmoa1911303

    Article  CAS  PubMed  Google Scholar 

  5. Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424. https://doi.org/10.1056/nejmoa2022190

    Article  CAS  PubMed  Google Scholar 

  6. James S, Erlinge D, Storey RF et al (2024) Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3. https://doi.org/10.1056/evidoa2300286

  7. Curtain JP, Docherty KF, Jhund PS et al (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42:3727–3738. https://doi.org/10.1093/eurheartj/ehab560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fernandes GC, Fernandes A, Cardoso R et al (2021) Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm 18:1098–1105. https://doi.org/10.1016/j.hrthm.2021.03.028

    Article  PubMed  Google Scholar 

  9. Asrial AA, Reviono R, Soetrisno S et al (2023) Effect of dapagliflozin on patients with rheumatic heart disease mitral stenosis. J Clin Med 12:5898. https://doi.org/10.3390/jcm12185898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Abdel-Qadir H, Carrasco R, Austin PC et al (2023) The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol 5:318–328. https://doi.org/10.1016/j.jaccao.2023.03.011

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hwang H-J, Kim M, Jun JE, Yon DK (2023) Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea. Sci Rep 13:1–10. https://doi.org/10.1038/s41598-023-48678-1

    Article  CAS  ADS  Google Scholar 

Download references

Funding

None

Author information

Authors and Affiliations

  1. Allama Iqbal Medical College, 164-C Faisal Town, Lahore, 54700, Pakistan

    Misha Mansoor & Muhammad Hamza Shafiq

  2. Lahore Medical and Dental College, Lahore, Pakistan

    Faisal Khalique

Authors
  1. Misha Mansoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Hamza Shafiq
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faisal Khalique
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Misha Mansoor.

Ethics declarations

Ethical approval

The submitted letter to editor titled The impact of SGLT 2 inhibitors: heart failure and beyond does not involve any intervention done on human and/or animals. No portion of the text has been copied from other material in the literature (unless in quotation marks, with citation).

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mansoor, M., Shafiq, M.H. & Khalique, F. The impact of SGLT 2 inhibitors: Heart failure and beyond. Ir J Med Sci (2024). https://doi.org/10.1007/s11845-024-03644-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11845-024-03644-2

Search

Navigation